drugset / Trial / NCT02695004

Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).

NCT02695004

Phase 1 Completed 44 enrolled Dongkook Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindOther

Summary

This is a study to evaluate safety, tolerability and PK of DKF-310 IM injection in healthy male volunteers.

Timeline

Start
2016-02
Primary completion
2017-03
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 35 mg Intramuscular
Subject Donepezil Small molecule 70 mg Intramuscular
Subject Donepezil Small molecule 140 mg Intramuscular
Subject Donepezil Small molecule 210 mg Intramuscular
Subject Donepezil Small molecule 280 mg Intramuscular

Indications